Diagnostic performance of breast ultrasonography and MRI in the prediction of lymph node status after neoadjuvant chemotherapy for breast cancer

Abstract

Background

Neoadjuvant chemotherapy (NAC) is widely used to treat breast cancer. Sentinel lymph node biopsy has replaced axillary lymph node dissection in patients who convert to node-negative status after NAC. However, few studies have evaluated the diagnostic performance of ultrasonography and magnetic resonance imaging (MRI) in determining axillary lymph node status after NAC.

Purpose

To evaluate the diagnostic performance of breast ultrasonography and MRI in determining residual metastatic axillary lymph node status after NAC for breast cancer and to identify histopathological factors affecting radiological performance.

Material and Methods

This study included 157 patients who underwent initial and follow-up preoperative breast ultrasonography and MRI before NAC between January and December 2010. The sensitivity, specificity, negative and positive predictive values, and accuracy of ultrasonography, MRI, and their combinations were evaluated.

Results

The sensitivity of ultrasonography, MRI, and their combination in post-NAC axillary imaging was 60.00%, 57.33%, and 65.33%, respectively; the specificity was 60.47%, 72.09%, and 60.47%, respectively. The positive predictive value was highest with MRI (78.18%). On univariate analysis, positive estrogen receptor status was associated with misdiagnosis by ultrasonography (P = 0.002), MRI (P = 0.002), and their combination (P = 0.001). When residual metastatic lymph nodes were present, lymph nodes with macrometastasis (>2.0 mm) were associated with correct ultrasonography-based diagnosis (P = 0.0027).

Conclusion

Imaging assists in predicting axillary lymph node status in patients undergoing NAC; however, is imprudent to omit sentinel lymph node biopsy or axillary lymph node dissection for staging in women determined to be node-positive.

Keywords

Neoadjuvant chemotherapy axillary lymph node metastasis breast neoplasm ultrasonography magnetic resonance imaging (MRI)

Get full access to this article

View all access options for this article.

References

Alvarado

Le-Petross

et al.

The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer. Ann Surg Oncol 2012; 19: 3177–3184.

Koolen

Valdes Olmos

Wesseling

et al.

Early assessment of axillary response with (1)(8)F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla. Ann Surg Oncol 2013; 20: 2227–2235.

Rouzier

Extra

Klijanienko

et al.

Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol 2002; 20: 1304–1310.

Straver

Rutgers

Russell

et al.

Towards rational axillary treatment in relation to neoadjuvant therapy in breast cancer. Eur J Cancer 2009; 45: 2284–2292.

You

Kang

Jung

et al.

Evaluation of lymph node status after neoadjuvant chemotherapy in breast cancer patients: comparison of diagnostic performance of ultrasound, MRI and (1)(8)F-FDG PET/CT. Br J Radiol 2015; 88: 20150143–20150143.

Cox

Bass

et al.

Sentinel lymphadenectomy: a safe answer to less axillary surgery?

Recent Results Cancer Res 1998; 152: 170–179.

Lucci

McCall

Beitsch

et al.

Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol 2007; 25: 3657–3663.

Kuehn

Bauerfeind

Fehm

et al.

Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol 2013; 14: 609–618.

Boughey

Suman

Mittendorf

et al.

Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA 2013; 310: 1455–1461.

10.

Boughey

Ballman

Hunt

et al.

Axillary ultrasound after neoadjuvant chemotherapy and its impact on sentinel lymph node surgery: results from the American College of Surgeons Oncology Group Z1071 Trial (Alliance). J Clin Oncol 2015; 33: 3386–3393.

11.

Saffar

Bennett

Metcalf

et al.

Retrospective preoperative assessment of the axillary lymph nodes in patients with breast cancer and literature review. Clin Radiol 2015; 70: 954–959.

12.

Mumtaz

Hall-Craggs

Davidson

et al.

Staging of symptomatic primary breast cancer with MR imaging. Am J Roentgenol 1997; 169: 417–424.

13.

Mortellaro

Marshall

Singer

et al.

Magnetic resonance imaging for axillary staging in patients with breast cancer. J Magn Reson Imaging 2009; 30: 309–312.

14.

Buchholz

Woodward

Duan

et al.

Radiation use and long-term survival in breast cancer patients with T1, T2 primary tumors and one to three positive axillary lymph nodes. Int J Radiat Oncol Biol Phys 2008; 71: 1022–1027.

15.

Mamounas

Anderson

Dignam

et al.

Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J Clin Oncol 2012; 30: 3960–3966.

16.

Bilimoria

Bentrem

Hansen

et al.

Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol 2009; 27: 2946–2953.

17.

Charfare

Limongelli

Purushotham

. Neoadjuvant chemotherapy in breast cancer. Br J Surg 2005; 92: 14–23.

18.

Brown

Hunt

Shen

et al.

Histologic changes associated with false-negative sentinel lymph nodes after preoperative chemotherapy in patients with confirmed lymph node-positive breast cancer before treatment. Cancer 2010; 116: 2878–2883.

19.

Javid

Segara

Lotfi

et al.

Can breast MRI predict axillary lymph node metastasis in women undergoing neoadjuvant chemotherapy. Ann Surg Oncol 2010; 17: 1841–1846.

20.

Hieken

Boughey

Jones

et al.

Imaging response and residual metastatic axillary lymph node disease after neoadjuvant chemotherapy for primary breast cancer. Ann Surg Oncol 2013; 20: 3199–3204.

21.

Schipper

Moossdorff

Beets-Tan

et al.

Noninvasive nodal restaging in clinically node positive breast cancer patients after neoadjuvant systemic therapy: a systematic review. Eur J Radiol 2015; 84: 41–47.

22.

Lee

Yoon

et al.

Diagnostic performance of 18F-FDG PET/CT, ultrasonography and MRI. Detection of axillary lymph node metastasis in breast cancer patients. Nuklearmedizin 2014; 53: 89–94.

23.

Rouzier

Perou

Symmans

et al.

Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 11: 5678–5685.

24.

Goldstein

Decker

Severson

et al.

Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer 2007; 110: 1687–1696.

25.

Carey

Dees

Sawyer

et al.

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007; 13: 2329–2334.

26.

Bhargava

Beriwal

Dabbs

et al.

Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases. Cancer 2010; 116: 1431–1439.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.06 MB